<div><em>Net profit for the quarter was adversely impacted by the one-time items as well as exceptional charges of Rs. 685 crore. <strong>C H Unnikrishnan </strong>reports</em><br><br>Sun Pharmaceutical Industries Ltd, India's largest generic drug maker by sales, posted about 60 per cent decline in net profit at Rs 479 crore for the June quarter of financial year 2016 as compared to the year-ago quarter mainly due to huge one-time charges including impairment on fixed assets and goodwill. The financials for this quarter include several exceptional charges related to the integration of Sun Pharma and Ranbaxy businesses.</div><div> </div><div> Its sales for the quarter at Rs. 6,522 crore was up 3 per cent over same quarter last year. While its sales in India at Rs. 1,784 crore was up 11 per cent this quarter, the high margin US sales down 4 per cent. </div><div> </div><div>Net profit for the quarter was adversely impacted by the one-time items as well as exceptional charges of Rs. 685 crore, the company said on Tuesday. </div><div> </div><div>Sun Pharma managing director Dilip Shanghvi said in a statement on Tuesday (11 August) that the company's performance for the quarter has been impacted by certain one-time and exceptional charges which will drive synergies and overall profitability improvement in the long-term. </div><div> </div><div>"Nonetheless, we continue to invest significantly in research and development and in building critical talent for enhancing our specialty and complex generics pipeline,” he added. </div>
